NCT01362361已完成2 期
TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 12
- 主要终点
- progression free survival
研究概览
简要总结
The purpose of this study:
To explore the comparative effectiveness of BIBF 1120 in terms of :
- Progression-free survival (PFS), objective response, overall survival
- Evaluate and compare safety
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven colorectal adenocarcinoma
- •Intended treatment with mFOLFOX6 after one prior palliative chemotherapy for metastatic CRC
- •Age > 18 years
- •Metastatic disease not suitable for curative-intent surgery
- •Measurable (> 1 cm) and evaluable disease (according to RECIST 1.1 criteria)
- •Prior bevacizumab, cetuximab or panitumumab are allowed.
- •Previous adjuvant oxaliplatin-containing therapy is allowed, if the end of adjuvant chemotherapy is >12 months prior to inclusion into the trial
- •ECOG performance status 0 or 1 (see appendix 10.4)
- •Adequate hepatic function
- •Adequate Renal function
- •Adequate bone marrow function
- •Other lab parameters: proteinuria < CTCAE grade 2, Prothrombin time and/or partial thromboplastin time < 50 % deviation from normal limits
- •Life expectancy at least 3 months
- •Signed and dated written informed consent prior to admission to the study in accordance with ICH-GCP guidelines and to the local legislation
排除标准
- •Known hypersensitivity to the trial drugs or their excipients.
- •Treatment with any investigational drug within 28 days of trial onset.
- •Prior treatment with more than one line of palliative standard chemotherapy for colorectal cancer, prior treatment with a tyrosine kinase inhibitor, prior palliative treatment with an oxaliplatin-containing regime.
- •History of other malignancies in the last 5 years, in particular those which could affect compliance with the protocol or interpretation of results. Patients with adequately treated basal or squamous cell skin cancer are generally eligible.
- •Serious concomitant disease, especially those that would limit compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
- •Major injuries and/or surgery or bone fracture within 4 weeks of trial inclusion, or planned surgical procedures during the trial period. Portimplantation prior to therapy is allowed.
- •Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 9 months, congestive heart failure > NYHA II) (see appendix 10.3).
- •History of severe haemorrhagic or thrombotic events in the past 12 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis). Known inherited predisposition to bleeds or to thrombosis.
- •Patient with brain metastases that are symptomatic and/or require therapy.
- •Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid ≤ 325mg per day)
- •History of major thrombotic or clinically relevant major bleeding event in the past 6 months
- •Current peripheral neuropathy ≥ CTCAE grade 2 except due to trauma
- •Serious infections requiring systemic antibiotic (e.g antiviral, antimicrobial, antifungal) therapy
- •Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
- •Active alcohol or drug abuse.
- •Women and men who are sexually active and unwilling to use a medically acceptable method of contraception
- •Pregnancy or breast-feeding
- •Leptomeningeal disease
- •Radiographic evidence of cavitary or necrotic tumours
- •Centrally located tumours with radiographic evidence (CT or MRI) of local invasion of major blood vessels
- •Severe chemotherapy-associated toxicity during or after adjuvant or palliative first-line chemotherapy like 5-FU-associated cardiac toxicity (coronary spasm) or persistent oxaliplatin-associated peripheral neuropathy (≥ CTCAE grade 2) with paresthesia associated with pain or functional impairment (after adjuvant oxaliplatin-containing chemotherapy).
研究组 & 干预措施
Arm A
Experimental
mFOLFOX6 + BIBF 1120
干预措施: mFOLFOX6 + BIBF 1120 (Drug)
Arm B
Placebo Comparator
mFOLFOX6+placebo
干预措施: mFOLFOX6+placebo (Drug)
结局指标
主要结局
progression free survival
时间窗: 1 year
次要结局
未报告次要终点
研究者
Prof. Dr. med. Thomas Seufferlein
PI
Martin-Luther-Universität Halle-Wittenberg
研究点 (12)
Loading locations...
相似试验
已完成
3 期
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00805194Boehringer Ingelheim1,314
已完成
2 期
Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 DiabetesType2 Diabetes MellitusNCT03655535Boston Therapeutics66
已完成
2 期
Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian CancerFallopian Tube CancerOvarian CancerNCT01610869University College, London117
终止
2 期
BIIB023 Proof-of-Concept Study in Participants With Lupus NephritisLupus NephritisNCT01499355Biogen276
招募中
3 期
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination TherapyEssential HypertensionType 2 Diabetes MellitusNCT06220773Boryung Pharmaceutical Co., Ltd276